Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — ASCO Annual Meeting 2024
13 slides from Cg Oncology's conference presentation, Jun 2, 2024
Slide 1: Attacking Bladder Cancer for a Better Tomorrow
Attacking Bladder Cancer for a Better Tomorrow | 1
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and
Slide 3: Final Results of CORE-001: Cretostimogene with Pembrolizumab in BCG-Unresponsive NMIBC
nog ASCO ANNUAL MEETING CorE-ool Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, High-Risk NMIBC with Carcinoma In Situ Roger Li, Paras Shah, Tyler Stewart, Trinity Bivalacqua, Donald Lamm,
Slide 4: Roger Li, M.D.
2 • ▪ ▪ • ▪ ▪ ▪ PRESENTED BY: Roger Li, M.D.
Slide 5: o o o
3 • o o o • • o • • PRESENTED BY: Roger Li, M.D.
Slide 6: Roger Li, M.D.
4 PRESENTED BY: Roger Li, M.D.
Slide 7: Recurrence Free Survival
5 • 100 90 80 • Recurrent Free Survival (%) 70 o 60 50 Total Median (95%) : N.A. (76.6, N.A.) Min, Max 11+, 145 • 40 o 30 20 • 10 CENSORED o 0 All Patients 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 • Time from Treatment Start (Weeks) No. at Risk No. Censored 35 0 35 0 33 1 28 4 27 5 22 6
Slide 8: Duration of Response
6 • 100 • Complete Response Rate (95% CI) 82.9 (66.4, 93.4) 90 80 o Duration of Response Survival (%) • 70 60 50 o 40 • 30 20 10 • CENSORED 0 All Patients o 0 10 20 30 40 52 60 70 80 90 104 110 120 130 140 No. at Risk 29 28 27 26 22 Time from Start of Response (Weeks) 22 19 18 18 9 6 5 3 1 0 o No. C
Slide 9: Roger Li, M.D.
7 • • • • • PRESENTED BY: Roger Li, M.D.
Slide 10: Roger Li, M.D.
8 • • • • • PRESENTED BY: Roger Li, M.D.
Slide 11: Roger Li, M.D.
9 • • • • • • • • • • • • • • • • • • • • PRESENTED BY: Roger Li, M.D.
Slide 12: Final Results of CORE-001 Summary
Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, High-Risk NMIBC with Carcinoma In Situ 100 ▪ ▪ 90 80 • Recurrent Free Survival (%) 70 ▪ 60 50 Median (95%) Min, Max ▪ Total : N.A. (76.6, N.A.
Slide 13: CG Oncology Inc. contact details
CG Oncology Inc. Information@cgoncology.com 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618 MediaRelations@cgoncology.com | 12